drugset / Trial / NCT00859118

Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

NCT00859118

Phase 1 Completed 30 enrolled University of Wisconsin, Madison Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to see what changes happen to the tumors while taking the axitinib and after it is stopped (during the scheduled breaks), and what changes in the tumor may be responsible for this growth. This will be done by using a special kind of scan called an 18F-FLT PET/CT. In addition, the investigators want to find out how the drugs are processed and distributed in the human body. The investigators will also look at how different types of cancer are affected by axitinib. The investigators will also correlate vasculature kinetics extracted from the dynamic FLT PET/CT imaging with the vasculature kinetics extracted from DCE-CT.

Timeline

Start
2009-02
Primary completion
2013-05
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 5 mg Oral

Indications